Ironwood Pharmaceuticals, Inc. (IRWD) Q3 2026 Earnings Call Transcript
Ironwood Pharmaceuticals, Inc. 2026 Q3 - Results - Earnings Call Presentation
Ironwood Pharmaceuticals Inc (IRWD) (Q3 2026) Earnings Call Highlights: Record LINZESS Sales ...
Ironwood (IRWD) Q3 2026 Earnings Call Transcript
What Ironwood Pharmaceuticals (IRWD) Said on Its Q3 Earnings Call
Ironwood Pharmaceuticals (IRWD) Beats Q3 Earnings Estimates
Ironwood: Q3 Earnings Snapshot
Ironwood Pharmaceuticals Raises Full-Year 2026 Financial Guidance Driven by Continued LINZESS U.S. Net Sales Growth and Strong Third Quarter Financial Performance
Ironwood Pharmaceuticals Q3 2026 Earnings Call Transcript
Ironwood Pharmaceuticals Raises FY2026 Sales Guidance from $460.000M-$485.000M to $485.000M-$510.000M vs $471.600M Est
Ironwood Pharmaceuticals Q3 Adj. EPS $0.36 Beats $0.32 Estimate, Sales $133.040M Beat $121.567M Estimate
Ironwood Pharmaceuticals to Host Third Quarter 2026 Investor Update Call
Ironwood Pharmaceuticals Appoints Tammi Gaskins as Chief Executive Officer
Ironwood Pharmaceuticals Appoints Tammi Gaskins CEO, Effective Jan. 1, 2027
Will Linzess Continue to Aid Ironwood's Top-Line Growth in Q3?
Ironwood Pharmaceuticals: The Stock Is A Call On The Second Apraglutide Trial - Buy
Ironwood Pharmaceuticals Reports Q2 2026 Results: Full Earnings Call Transcript
Ironwood: Medicare Is Not The Problem I Thought It Was
Ironwood Pharmaceuticals to Participate in the Wells Fargo 21st Annual Healthcare Conference
Ironwood Pharmaceuticals: High Dependence On Its Next Trial
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.